- Home
- AVTX vs IMUX Comparison
AVTX vs IMUX Comparison
Compare AVTX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- IMUX
- Stock Information
- Founded
- AVTX 2011
- IMUX 2016
- Country
- AVTX United States
- IMUX United States
- Employees
- AVTX N/A
- IMUX N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- IMUX Health Care
- Exchange
- AVTX Nasdaq
- IMUX Nasdaq
- Market Cap
- AVTX 90.9M
- IMUX 100.0M
- IPO Year
- AVTX 2015
- IMUX N/A
- Fundamental
- Price
- AVTX $9.09
- IMUX $1.07
- Analyst Decision
- AVTX Strong Buy
- IMUX Strong Buy
- Analyst Count
- AVTX 4
- IMUX 6
- Target Price
- AVTX $33.00
- IMUX $12.67
- AVG Volume (30 Days)
- AVTX 141.8K
- IMUX 841.9K
- Earning Date
- AVTX 11-07-2024
- IMUX 02-20-2025
- Dividend Yield
- AVTX N/A
- IMUX N/A
- EPS Growth
- AVTX N/A
- IMUX N/A
- EPS
- AVTX N/A
- IMUX N/A
- Revenue
- AVTX $820,000.00
- IMUX N/A
- Revenue This Year
- AVTX N/A
- IMUX N/A
- Revenue Next Year
- AVTX N/A
- IMUX N/A
- P/E Ratio
- AVTX N/A
- IMUX N/A
- Revenue Growth
- AVTX N/A
- IMUX N/A
- 52 Week Low
- AVTX $3.95
- IMUX $0.97
- 52 Week High
- AVTX $34.46
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- AVTX 37.40
- IMUX 42.08
- Support Level
- AVTX $9.00
- IMUX $1.00
- Resistance Level
- AVTX $9.99
- IMUX $1.10
- Average True Range (ATR)
- AVTX 0.89
- IMUX 0.08
- MACD
- AVTX -0.01
- IMUX -0.02
- Stochastic Oscillator
- AVTX 27.07
- IMUX 20.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.